The present invention relates to methods for predicting prolonged survival and treatment susceptibility of brain cancer patients and in particular to methods for predicting prolonged survival and increased treatment susceptibility of glioblastoma multiforme (GBM) patients. The invention further relates to compositions for use in the treatment of GBM patients and in particular to cytokine supplementation, cytokine depletion and immunotherapeutic compositions. Embodiments of the invention have been particularly developed for identifying CBM patients with particular cytokine profiles or responses in peripheral blood cerebrospinal fluid (CSF), bone marrow or tumour infiltrating lymphocytes (TIL) samples obtained prior to tumour surgery and will be described hereinafter with reference to this application. However, it will be appreciated that the invention is not limited to this particular field of use.
